On the final day of the annual J.P. Morgan Healthcare Conference, Richard Francis, with vast experience at Biogen and Sandoz under his belt, faced investors for the first time as Teva’s CEO, after replacing Kåre Schultz on 1 January.
Richard Francis may only have sat in the Teva CEO seat for ten days, but he faced down delegates to the world’s foremost healthcare symposium to provide his early thoughts on the Israeli giant, and the first steps to begin the process of turning around the company’s fortunes.
Indeed, Francis’ words took on an additional edge as his host, J.P. Morgan, had less than two months ago downgraded...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
